hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06267417, orgStudyIdInfo id: CCHE-AML-4/2023, briefTitle: Laser Therapy Effect as Preventive Measure for Oral Mucositis in Children With Hematological Malignancies, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-10, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Children's Cancer Hospital Egypt 57357, class: OTHER, descriptionModule briefSummary: Introduction:Among the most drastic complications of chemotherapy is oral mucositis(OM). It is a painful inflammatory, often ulcerative condition and may increase risk for systemic infections leading to prolonged hospital stays and interruptions of treatment protocol. Many treatment modalities have been introduced for the prevention and treatment of oral mucositis, of which low level laser therapy(LLLT) is gaining popularity. The use of LLLT as a prophylactic treatment for chemotherapy induced oral mucositis in pediatric cancer patients is still lacking robust evidence. Also, the parameters used have not been optimized and no standard method has yet been established. Based on this point, this study will compare photobiomodulation to the conventional preventive program of oral mucositis applied in 57357 children's cancer hospital foundation to determine which will be optimal for the prophylaxis of chemotherapy-induced OM.Aim:To assess the effectiveness of low level laser therapy in the prophylaxis of oral mucositis in pediatric patients diagnosed with Hematological cancers.Methods:This study is a randomized, prospective, double-blinded trial that will include acute Myeloid leukemia patients admitted to receive chemotherapy cycle between the age of 3 and 18years. These patients will be randomized into two groups: group 1 will receive low level laser therapy and group 2 will receive mock treatment. Patient will be followed to asses the development of oral mucositis on prespecified time points., conditionsModule conditions: Oral Mucositis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, maskingDescription: The outcome evaluator will be a single personnel from the oncology team following up with the case, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: Laser therapy, interventions name: Mock treatment, outcomesModule primaryOutcomes measure: To measure incidence of oral mucositis in Laser arm versus Placebo arm., primaryOutcomes measure: To measure grade of oral mucositis in patients receiving laser arm placebo arm., eligibilityModule sex: ALL, minimumAge: 3 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Children Cancer Hospital 57357, status: RECRUITING, city: Cairo, zip: 11617, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06267404, orgStudyIdInfo id: IShamsi, briefTitle: Effectiveness of Iliopsoas Positional Release Versus Conventional Exercises in the Management of Sub-acute Back Pain., statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2025-02-15, completionDateStruct date: 2025-02-25, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-22, sponsorCollaboratorsModule leadSponsor name: University of Karachi, class: OTHER, collaborators name: Sindh Institute of Physical Medicine and Rehabilitation, descriptionModule briefSummary: Recommended treatment for chronic non-specific LBP is exercise therapy, behavioral therapy including pain management, or a combination of these; There is not enough evidence to establish recommendations for which one is the most appropriate.The primary objective of this study is to explore the effects of Ilio-psoas Release on Sub-acute back pain, ROM \& functional disability, conditionsModule conditions: Back Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Iliopsoas Positional release therapy, interventions name: Conventional exercises, outcomesModule primaryOutcomes measure: VAS Visual Analogue Scale VAS Visual Analogue Scale, primaryOutcomes measure: Modified Schober's test, secondaryOutcomes measure: Roland-Morris Disability Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Sindh Institute of Physical Medicine and Rehabilitation, status: RECRUITING, city: Karachi, state: Sindh, country: Pakistan, contacts name: Iram I Shamsi, MPhil, role: CONTACT, contacts name: Iram I Shamsi, MPhil, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 24.8608, lon: 67.0104, hasResults: False
protocolSection identificationModule nctId: NCT06267391, orgStudyIdInfo id: 898, briefTitle: Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes, acronym: ReCET, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-10-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Endogenex, Inc., class: INDUSTRY, descriptionModule briefSummary: This study is designed to evaluate the safety and effectiveness of endoscopic intestinal re-cellularization therapy in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering medications., conditionsModule conditions: Type 2 Diabetes Mellitus, conditions: Type2diabetes, conditions: Diabetes Mellitus, Type 2, conditions: Diabetes, conditions: Type 2 Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: The participants randomized in a 2:1 ratio to the ReCET treatment arm or the sham control arm., primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 264, type: ESTIMATED, armsInterventionsModule interventions name: ReCET Treatment, interventions name: Sham Procedure, outcomesModule primaryOutcomes measure: HbA1c, secondaryOutcomes measure: HbA1c, secondaryOutcomes measure: HbA1c ≤7.0% without requiring rescue medication, secondaryOutcomes measure: Time-in Range (TIR), secondaryOutcomes measure: Total body weight loss (%TBWL), secondaryOutcomes measure: Incidence of adverse events, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06267378, orgStudyIdInfo id: 1174/2022/NCTS, briefTitle: Assessing Frailty and Its Impacts on Patients Facing Major GI Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-30, primaryCompletionDateStruct date: 2024-12-01, completionDateStruct date: 2029-12-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Doncaster And Bassetlaw Hospitals NHS Foundation Trust, class: OTHER, descriptionModule briefSummary: The study team will look at 3 new tests that will make it easier to measure frailty in patients awaiting surgery for cancer and compare them against standard clinical measures of frailty in a pilot study. The expected outcome is that evidence will be collated in order to apply for a major grant to look at improving the care of frail patients with cancer in the future., conditionsModule conditions: Bowel Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Frailty measure, outcomesModule primaryOutcomes measure: The sensitivity & specificity of digital motion data for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events, primaryOutcomes measure: The sensitivity & specificity of tissue senescence for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events, primaryOutcomes measure: The sensitivity & specificity of blood based biomarkers for the prediction of baseline clinical frailty levels & post-operative measures of frailty, mortality and adverse events, secondaryOutcomes measure: Blood biomarker correlation (baseline and post operative) with baseline frailty and poor outcomes (including length of stay and adverse events), secondaryOutcomes measure: Adverse events related to surgery assessed CTCAE classifications, secondaryOutcomes measure: Tissue senescence correlation between baseline frailty and poor outcomes (including length of stay and adverse events), secondaryOutcomes measure: Digital mobility outcomes correlation with baseline frailty and poor outcomes (including length of stay and adverse events), secondaryOutcomes measure: Physical function assessment after surgery at 6 weeks, 3 months using the WHO DAS 2.0., secondaryOutcomes measure: Quality of life at 6 weeks, 3 months after surgery using the EQ-5D-5L, secondaryOutcomes measure: Overall survival at 3 months and 5 years (the latter via cancer registry returns), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, status: RECRUITING, city: Doncaster, state: South Yorkshire, zip: DN2 5LT, country: United Kingdom, contacts name: Doncaster Royal Infirmary, role: CONTACT, email: dbth.clinicalresearch@nhs.net, geoPoint lat: 53.52285, lon: -1.13116, hasResults: False
protocolSection identificationModule nctId: NCT06267352, orgStudyIdInfo id: 230097, briefTitle: Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology, acronym: NEOSAUR, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-06, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: University Hospital, Caen, class: OTHER, descriptionModule briefSummary: Newborns hospitalized in Neonatology are particularly vulnerable to infections, in particular healthcare associated infection (HAI). Staphylococcus aureus represents the 2nd microorganism responsible for sepsis, this infection is particularly serious and like any HAI, it increases the length of hospitalization of newborns and neonatal morbidity.In September 2020, the CDC published recommendations for the prevention and control of Staphylococcus aureus infections in neonatal intensive care unit/ICU. They specify the indications for implementing a MSSA surveillance strategy as well as the screening and management methods.Despite the absence of a defined strategy at the national level, our establishment chose to initiate management measures several years ago following serious infections and MSSA epidemics in neonatal intensive care unit/ICU.With the aim of improving the efficiency of care and evaluating the strategy chosen at the establishment, it is necessary to describing* the epidemiology of MSSA carriage and infections* cross-transmission of MSSA strains between patients* the success rate of decolonization* the sensitivity of detection of digestive carriage by stool swabbing in order to limit the number of samples from newborns., conditionsModule conditions: the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 120, type: ESTIMATED, outcomesModule primaryOutcomes measure: frequency of MSSA cross transmission as assessed by WGS, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06267339, orgStudyIdInfo id: TD_tRNS, briefTitle: Effects of Transcranial Random Noise Stimulation on Motor Learning in Typically Developing Adolescents, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2026-08-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Burke Medical Research Institute, class: OTHER, descriptionModule briefSummary: The goal of this study is to compare motor learning rates on two different tasks, when combined with non-invasive brain stimulation., conditionsModule conditions: Children, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: transcranial random noise stimulation, interventions name: Sham stimulation, outcomesModule primaryOutcomes measure: Change in Grasp score, primaryOutcomes measure: Change in Reach score, secondaryOutcomes measure: Change in Graded Redefined Assessment of Strength, Prehension assessment (GRASSP), secondaryOutcomes measure: Change in score on second reaching task, eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Burke Neurological Institute, city: White Plains, state: New York, zip: 10605, country: United States, geoPoint lat: 41.03399, lon: -73.76291, hasResults: False
protocolSection identificationModule nctId: NCT06267326, orgStudyIdInfo id: Nasser institute, briefTitle: World Health Organization (WHO), COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-23, primaryCompletionDateStruct date: 2022-06-12, completionDateStruct date: 2023-08-21, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Nasser Institute For Research and Treatment, class: OTHER_GOV, descriptionModule briefSummary: Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection, conditionsModule conditions: Mucormycosis; Rhinocerebral (Etiology), conditions: COVID-19, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: CARE_PROVIDER, enrollmentInfo count: 35, type: ACTUAL, armsInterventionsModule interventions name: debridment, outcomesModule primaryOutcomes measure: 35 patients suffering from mucormycosis infection post covid 19, primaryOutcomes measure: 25 patients were cured with comorbidity and 10 pateints died, primaryOutcomes measure: pain, secondaryOutcomes measure: Visual Analog Score for pain, eligibilityModule sex: ALL, minimumAge: 22 Years, maximumAge: 77 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Omar Elmonofy, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06267313, orgStudyIdInfo id: 2023-078-PAU, briefTitle: Attention Training for COVID-19 Related Distress, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2027-02-19, completionDateStruct date: 2027-02-19, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: Palo Alto University, class: OTHER, descriptionModule briefSummary: The study aims to test whether attention training (attention bias modification or attention control training) reduces distress or COVID-19 related anxiety compared to a neutral condition., conditionsModule conditions: Anxiety, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Attention Bias Modification, interventions name: Attention Control Training, interventions name: Neutral training, outcomesModule primaryOutcomes measure: COVID-19 Anxiety Syndrome Scale, primaryOutcomes measure: COVID-19 Anxiety Syndrome Scale, primaryOutcomes measure: COVID-19 Anxiety Syndrome Scale, primaryOutcomes measure: COVID-19 Anxiety Syndrome Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Palo Alto University, status: RECRUITING, city: Palo Alto, state: California, zip: 94304, country: United States, contacts name: Mikael Rubin, PhD, role: CONTACT, phone: 650-433-3805, email: mrubin@paloaltou.edu, geoPoint lat: 37.44188, lon: -122.14302, hasResults: False
protocolSection identificationModule nctId: NCT06267287, orgStudyIdInfo id: 2023-4, briefTitle: Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-01-01, primaryCompletionDateStruct date: 2022-12-31, completionDateStruct date: 2022-12-31, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-02-20, sponsorCollaboratorsModule leadSponsor name: Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty, class: OTHER, descriptionModule briefSummary: Background. Infection is the most common complication of complications after joint arthroplasty. During the COVID-19 pandemic increased used antibacterial drugs by adults, this could change the spectrum of infectious agents and their antimicrobial resistance. The purpose of the study is to evaluate the microbial diversity of pathogens of periprosthetic infection in the pre- and post-Covid period, determining the sensitivity of the leading pathogens to antibiotics. Materials and methods. A comprehensive comparative retrospective study was carried out on 342 cases of monomicrobial and polymicrobial periprosthetic infection (PPI) of limb joints with microbiological growth of microorganisms in the pre-Covid (2018-2019) and post-Covid (2021-2022) periods., conditionsModule conditions: Joint Infection, conditions: Periprosthetic Left Knee Joint Infection, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 342, type: ACTUAL, armsInterventionsModule interventions name: Microbiological examination of the patient's biological material and determination of antibiotic resistance, outcomesModule primaryOutcomes measure: Structure of isolated pathogens of periprosthetic infection, primaryOutcomes measure: Structure of isolated pathogens of periprosthetic infection, secondaryOutcomes measure: Antibiotic resistance of isolated pathogens of periprosthetic infection, secondaryOutcomes measure: Antibiotic resistance of isolated pathogens of periprosthetic infection, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Federal Center for Traumatology, Orthopedics and Endoprosthetics, city: Cheboksary, state: Chuvashia, zip: 429500, country: Russian Federation, geoPoint lat: 56.13222, lon: 47.25194, hasResults: False
protocolSection identificationModule nctId: NCT06267274, orgStudyIdInfo id: MW230021, briefTitle: A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-02-20, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Amneal Pharmaceuticals, LLC, class: INDUSTRY, collaborators name: CBCC Global Inc., collaborators name: Amneal EU, Limited, descriptionModule briefSummary: A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study, conditionsModule conditions: Open-angle Glaucoma, conditions: Ocular Hypertension, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Subjects will be randomized in such way that ratio of treatment distribution will be nearer to 1:1 between the treatment arms, and within the combined stratification criteria., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: double-blind study, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: Bimatoprost Ophthalmic Solution, 0.01%, interventions name: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, outcomesModule primaryOutcomes measure: Primary Endpoint, secondaryOutcomes measure: Secondary Endpoint, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: West Coast Eye Institute, city: Bakersfield, state: California, zip: 93308, country: United States, contacts name: Sandeep Walia, MD, role: CONTACT, geoPoint lat: 35.37329, lon: -119.01871, locations facility: Eye Research Foundation, city: Newport Beach, state: California, zip: 92663, country: United States, contacts name: David Wirta, MD, role: CONTACT, geoPoint lat: 33.61891, lon: -117.92895, locations facility: Clayton Eye Research, city: Morrow, state: Georgia, zip: 30260, country: United States, contacts name: Kim Jong, MD, role: CONTACT, geoPoint lat: 33.58317, lon: -84.33937, locations facility: Houston Eye Associates, city: Houston, state: Texas, zip: 77008, country: United States, contacts name: Kevin Jong, MD, role: CONTACT, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False